Chikara Murakata
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Microtubule and mitosis dynamics, Bioactive Compounds and Antitumor Agents, HER2/EGFR in Cancer Research, Carbohydrate Chemistry and Synthesis
Most-Cited Works
- → K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases(1987)942 cited
- → Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation(2000)308 cited
- → Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives(1992)146 cited
- KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.(1999)
- Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).(1999)
- → Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives(1997)119 cited
- → Stereoselective total synthesis of the glycosyl phosphatidylinositol (GPI) anchor of Trypanosoma brucei(1992)118 cited
- Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).(1998)
- → Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex(2000)100 cited
- → Mixed lineage kinase activity of indolocarbazole analogues(2002)94 cited